Johnson & Johnson Innovation – JJDC, Inc.

Investing in and supporting the
global entrepreneurial community

Learn more

About us


Johnson & Johnson Innovation – JJDC, Inc. (JJDC) is focused on growing companies, not just investments. As the strategic venture capital arm of Johnson & Johnson, we pursue opportunities to solve critical healthcare needs. Our partners benefit from the full global capabilities of Johnson & Johnson as we collaborate to drive innovation. 


JJDC 2018 Newsletter

2018 marks an important milestone for JJDC as we celebrate our 45th anniversary as strategic investors for the Johnson & Johnson Family of Companies.

Click here to view newsletter

JJDC finds transformative ideas and helps them mature into real solutions for today’s patients. 

Guided by a clear, consistent investment strategy aligned with scientific goals, JJDC works hand-in-hand with partners to navigate the path to creating breakthrough health innovations. 

We invest across sectors—pharmaceuticals, medical devices and consumer healthcare—and at all stages, from seed-level startups to Series B and beyond.  

All of our portfolio companies receive the same unwavering commitment. We take a long-term approach, deploying the full capabilities of the Johnson & Johnson family of companies, including discovery, clinical development, regulatory affairs, manufacturing and commercialization. 

Our team includes leaders in the healthcare and technology communities, many with deep R&D experience. This gives us the ability to understand our partners and provide the help they need. 

Every opportunity is unique, with tailored roles and terms that provide the best path to success. 


  • Tom Heyman
    President JJDC
  • Jeanne Bolger
    Jeanne Bolger
    Vice President, Venture Investments
  • Renee Compton Ryan
    Renee Compton Ryan
    Vice President, Venture Investments
  • Maciek Drozdz
    Principal, Venture Investments
  • Stacy Feld
    Vice President of Consumer Venture Investments and External Innovation
  • V. Kadir Kadhiresan, PhD
    V. Kadir Kadhiresan
    Vice President, Venture Investments
  • Ajay Khatri
    Ajay Khatri
    Director, Venture Investments
  • Tamir Meiri JJDC
    Tamir Meiri
    Senior Manager of Venture Investments
  • Vijay Murthy
    Principal, Venture Investments
  • Marian Nakada
    Marian Nakada
    Vice President, Venture Investments
  • Asish K. Xavier
    Vice President, Venture Investments
  • Zeev Zehavi
    Vice President, Venture Investments


We’re positively impacting human health through innovation. To do this, we identify the best opportunities across all sectors and allow innovators to leverage Johnson & Johnson’s many resources.

We’ve Been There Before

Our highly experienced team hails from throughout the healthcare and technology venture communities, many of us bringing deep R&D experience in addition to investment acumen. Just like you, we are entrepreneurs, scientists and studied risk-takers. Our team’s unique vantage point gives us an exceptional ability to understand the challenges and provide the right kind of help at the right time.    

Investing With Impact 

We have dedicated teams focused on investing at all stages of innovation, and across all four sectors: pharmaceuticals, medical devices, consumer health and global public health. We seek innovations with potential to make a transformational impact in the health and lives of people around the globe. 

If your early-stage company is looking to advance a program that is pre-proof of concept in humans, connect with one of our Johnson & Johnson Innovation Centers, located around the globe in the life science hot spots of Asia Pacific, Boston, California and London.

Each Investment Is Unique

At JJDC, there’s no such thing as a one-size-fits-all approach. We understand that each idea is unique, requiring an equally distinct investment strategy. We customize every deal to the opportunity, ranging from Seed and Series A investments in the earliest-stage startups to Series B investments and beyond in more mature companies. We also make private investments in public equity.

Creating Thriving Enterprises

For more than 40 years, JJDC has made investments in hundreds of innovative companies across pharmaceuticals, medical devices and consumer healthcare. Once we invest, we’re committed to you. We believe in value-add investing, playing an active role in providing strategic direction and enabling access to internal experts across the Johnson & Johnson Family of Companies.

Focus Areas

JJDC is seeks ideas that align with our business priorities in our Pharmaceuticals, Consumer and Medical Devices sectors. In each sector, we focus on specific therapeutic areas of interest that have the greatest potential to improve the lives of patients and consumers.

CLICK a business area of interest below
  • Consumer
  • Medical Devices
  • Pharmaceuticals
  • Global Public Health
CLICK on a circle to see the areas we are targeting
  • Baby Skin, Mother & Baby
    Baby Care
    Baby Care
  • Healthy Skin, Digital Beauty, Naturals
  • Novel Wound Healing Solutions
    Wound Care
    Wound Care
  • Sustainable Materials
    Feminine Personal Care
    Feminine Personal Care
  • Biofilm Innovation, Whitening Technologies
    Oral Care
    Oral Care
  • Pain Care, Digestive Health, Allergy Prevention & Solutions, Smoking Cessation, Cough & Colds


  • IMAGE Overseas Businesswoman of the Year Award: Dr. Jeanne Bolger

    Read more
  • Read the MedCity News Survey on Corporate Venture Capital in Healthcare

    Read more
  • Lake Whillans Research of VC Strategics in Life Sciences

    Read more


Portfolio Company News

  • Carrot Inc. Raises $25 Million to Commercialize Pivot, the Company's Digital Health Solution for Smoking Cessation

    Digital health company Carrot Inc. today announced that it has raised a $25 million round to commercialize its Pivot™ smoking cessation program ( JJDC led the round, joined by New York Life Ventures and existing investors Khosla Ventures, Marc Benioff, Carrot founder David S. Utley, M.D., and R7 Partners. An investor from JJDC will join Carrot's board of directors.

    Read More
  • CuraSen Therapeutics Announces $54.5 Million Series A Financing with Industry Veterans at Helm to Develop Drugs Targeting Novel Mechanism for the Treatment of Neurodegenerative Diseases

    Read More
  • Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen

    Read More
  • Twentyeight-Seven Therapeutics Launches with a $65 Million Series A Funding

    Twentyeight-Seven Therapeutics (28-7), a biotechnology company focused on modulating non-coding RNA (ncRNA) biology to develop treatments for cancer and other diseases, today announced the successful completion of its $65 million Series A financing. Founding investor MPM Capital and Novartis Venture Fund co-led the financing.

    Read More
  • Accelerator Life Science Partners Launches Magnolia Neurosciences Corporation with $31 Million Series A to Develop Targeted Neuroprotective Therapies

    Accelerator Life Science Partners (Accelerator), a leading life science investment and management firm, today announced that it has launched Magnolia Neurosciences Corporation, a company developing a new class of neuroprotective medicines. Co-founded by Accelerator and The University of Texas MD Anderson Cancer Center (MD Anderson), the company will further develop discoveries made by scientists in MD Anderson’s Therapeutics Discovery division and the Neurodegeneration Consortium (NDC).

    Read More



Make the Connection

We look forward to our first discussion.  If you would like to discuss a collaboration,
simply click the contact us button which will connect you to our Idea Portal and a member of our team will contact you.



Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.